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Abstract  
Male hypogonadism has been treated with exogenous testosterone since the 1930’s. The 
early transdermal patches of testosterone became available in the 1980’s with gel and solution 
preparations following in subsequent decades. This review focusses on the skin permeation 
characteristics of testosterone, pharmacokinetics following application of transdermal formulations 
and formulations currently available. At present, gels dominate the market for transdermal 
testosterone replacement therapy, presumably because of their greater patient acceptability and 
non-occlusive nature compared with patches. However, specific incidences of secondary transfer of 
gels to children with consequent unwanted effects such as precocious puberty have been reported. 
A regulatory review of all testosterone replacement therapies is currently underway which may have 
implications for future prescribing practices of transdermal testosterone products.    
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Highlights 
1) Transdermal testosterone delivery has come of age with a variety of technologies currently 
available to patients 
2) Pharmacokinetics and metabolism of testosterone following transdermal delivery are 
detailed 
3) Advantages and disadvantages of various formulations are discussed  
 
 
Abbreviations: AUC, area under the plasma concentration time curve; Cmax, maximum plasma 
concentration; C’ss, time averaged steady state testosterone concentrations; DHT, 
dihydrotestosterone; DMAC, dimethyl acetamide; DMF, dimethyl formamide;  DMSO, dimethyl 
sulphoxide; FSH, follicle-stimulating hormone;  LH, luteinizing hormone; MO,  mineral oil; PG, 
propylene glycol; SHBG, sex hormone binding globulin. 
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1. Introduction   
Testosterone (Figure 1) is an androgenic steroid hormone which regulates a number of 
important functions in males including sperm production, sex drive, fat distribution, muscle mass, 
bone density and red blood cell production.  Production of testosterone in the testes is regulated by 
luteinizing hormone (LH) in the pituitary gland. Puberty starts with the production of LH and follicle-
stimulating hormone (FSH), the latter hormone being critical for spermatogenesis. The action of 
testosterone is via the androgen receptor, located in the nucleus and cytoplasm of target cells. 
Deficiency or absence of testosterone in men is defined as hypogonadism which is further classified 
as either primary (originating in the testes) or secondary (resulting from a problem in the 
hypothalamus or pituitary gland). Testosterone deficiency may result from autoimmune conditions 
(Addison’s disease or hypoparathyroidism), genetic disorders (Klinefelter’s or Turner’s syndrome) or 
may result for other reasons including accidents, infection, excessive exposure to heavy metals or 
alcohol, radiation, chemotherapy and tumours. With age, males experience declining testosterone 
levels and loss of the normal diurnal rhythm of testosterone which may also result in clinical 
hypogonadism (1).  
The symptoms of hypogonadism include impaired libido, loss of sexual function, regression 
of secondary sex characteristics, low muscle mass and decreased bone density (2,3). The primary 
approach for management of this condition is testosterone replacement therapy. Testosterone is 
currently administered to hypogonadal patients using various routes including oral, parenteral 
(injection or implant) and transdermal delivery. Although transdermal testosterone delivery devices 
first became available in the 1980’s, percutaneous administration of testosterone for treatment of 
hypogonadism was reported as early as the 1930’s (4). Transdermal delivery of testosterone offers a 
number of advantages compared with other routes of delivery including improved patient 
compliance, ease of administration and / or cessation of therapy and the achievement of sustained 
drug plasma levels. The goal of effective transdermal testosterone delivery is to achieve plasma 
levels in the range of normal endogenous production of 3 – 10 mg over 24 h and in a time 
dependent manner thus mimicking the circadian profiles of healthy males (5,6). In this article the 
historical development of transdermal testosterone formulations is reviewed as well as the various 
formulations currently available. Emerging technologies are also considered as well as safety 
considerations for steroidal hormone formulations.  
 
2. Physicochemical properties, pharmacokinetics and metabolism  
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The physicochemical properties and pharmacokinetics of testosterone are summarised in 
Table 1.  
 When administered orally, testosterone is subject to significant metabolism in the 
gastrointestinal tract (13) and in the liver (14). Following intravenous injection, the half-life of 
testosterone in blood has been reported to vary from 10-100 min (9,10). Testosterone is 
metabolised to several keto derivatives via oxidation at the 17-OH group as well as to 
dihydrotestosterone (DHT) and estradiol. Metabolites are excreted as glucuronide or sulphate 
conjugates (9) with about 6% of drug being excreted unchanged (11). In the systemic circulation 
testosterone is bound to sex hormone binding globulin (SHBG) tightly, and loosely to albumin with a 
small amount (~2%) of the free molecule (15,16). Total testosterone measurement is accepted for 
evaluation of most patients, however free testosterone is determined in some cases because of 
changes in SHBG concentration with health status, age or drug therapy (17).  
Testosterone is metabolised in adipose tissue and skin by 5 reductase and aromatase to 
DHTand estradiol, respectively (18). Higher levels of reductase are found in perianal skin areas e.g. 
the scrotum (19) explaining the elevated levels of DHT observed in studies with scrotal patches (20, 
21). Long term exposure to testosterone has also been suggested to increase 5 reductase levels in 
hypogonadal men (22). The potential long terms effects of elevated DHT associated with scrotal 
patches raised concerns as elevated DHT levels had earlier been reported in prostate hyperplasia 
(23).   
 
3. Testosterone skin permeation  
 Christophers and Kligman (24) reported the measurement of testosterone absorption in vivo 
using a residual analysis technique in 10 young (19-30 years) and 10 old (71–82 years) subjects. The 
site on the back was first cleansed with ether followed by application of 0.02 ml of a 1% solution of 
14C testosterone in ethylene glycol monomethyl ether over an area of ~1.8 cm2.  Silicone vacuum 
grease was used to ensure no spreading of the solutions and initial counts were taken after drying of 
the application. Following occlusion of the site with Saran Wrap for 24 h final radioactivity was 
measured. The difference between the initial and final counts indicated 38% absorption for younger 
subjects and 13% absorption for older subjects. However it should be noted that this study does not 
necessarily show that this high amount was absorbed into the circulation; there may be some 
remaining in the stratum corneum. In a later study by Roskos et al (25), where direct measurement 
of testosterone was conducted, no significant differences in testosterone absorption for younger 
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and older subjects were observed. Radiolabelled testosterone was applied to the forearm in an 
acetone vehicle at a dose of 4 g/cm2. Urinary testosterone measurements indicated that the 
percentage dose absorbed for the young group (22–40 years) was 19.0 ± 4.4% and for the old group 
the value was 16.6 ± 2.5%.  Measurement of testosterone from the human forearm was also 
reported by Feldman and Maibach in a number of earlier studies (26,27). Radiolabelled testosterone 
was dosed at 0.06 mg/13 cm2 in an acetone vehicle containing 25% of either dimethyl formamide 
(DMF), dimethyl acetamide (DMAC), dimethyl sulphoxide (DMSO), mineral oil (MO) or propylene 
glycol (PG). Treated sites were not protected in any way and subjects were requested not to wash 
the areas for one day. The urine of subjects was collected for five days and analysed with 11.8% of 
the radiolabel being excreted for the control vehicle (acetone alone). DMSO and DMF increased the 
penetration of testosterone by four and two-fold, respectively.  DMAC and PG also increased 
testosterone permeation. but to a lesser extent and MO had no effect compared with the control. In 
a later study, conducted under similar condition, the amount of testosterone absorbed from an 
acetone vehicle was reported as 13% of the applied dose (28).  Schaefer et al (29) estimated the flux 
of testosterone through skin as 0.05 nmol/cm2/h over a 12 – 24 h period, based on the earlier work 
of Maibach and colleagues.  The authors also determined a flux value for testosterone of 1 x 
nmol/cm2/h for a 0.1% preparation based on in vitro experiments over 100 min; as this is a relatively 
short time, steady state is not likely to have been achieved.   
Bucks et al. (30) reported values of ~20% of testosterone absorbed for a repeated 
application study in five healthy male volunteers. Testosterone was applied in an acetone vehicle 
over a 28 cm2 area of the forearm at a dose of 4 g/cm2; radiolabelled compound was applied on 
days 1 and 8 while unlabelled material was applied for days 2 to 7 and days 9 to 14. The application 
site was washed every day prior to application of the next dose and urine was collected daily for 14C 
analysis. In a later study (31), testosterone absorption in vivo was studied for occluded versus 
“protected” (covered but not occlusive) conditions. Following a single dose application the 
percentage of drug absorbed for the occluded studies was higher (46%) compared with the 
protected conditions (18%). For multiple doses applied at the same skin site (daily application at the 
same skin site for 14 days) drug absorption at day 8 was not significantly different compared with 
the single dose occluded study (~50%).  
 
4. Transdermal testosterone patch formulations  
Scrotal patches 
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Most of the matrix scrotal patches developed by Alza which were evaluated in the early 
clinical studies were available in three sizes; 20 cm2, 40 cm2 or 60 cm2 with respective drug content 
being 5 mg, 10 mg and 15 mg.  Approximately one third of the drug content was delivered from the 
patches.  Elevated levels of DHT and high ratios of DHT to testosterone, associated with the elevated 
reductase enzyme activity, were observed after 2-4 weeks continuous use of the patches (21,22, 32).  
 Trans-scrotal patches achieved testosterone levels of 400 ng/ml or greater, in hypogonadal 
subjects, in less than 4 h (33), with dose dependent increases depending on patch size. Six patients 
underwent five one-week treatments with patches being applied for 22 h daily. Subjects wore a 
placebo patch for the first week and then were treated with 20, 40 or 60 cm2 patches containing 5, 
10 and 15 mg of testosterone, respectively. Mean average testosterone serum levels for placebo and 
for the patches were 135 ± 38 ng/dL, 348 ± 66 ng/dL, 455 ± 77ng/dl and 624 ± 65 ng/dl. Korenman et 
al. (22) reported the results of short and long-term treatment with trans-scrotal patches for three 
patients. For the former, patches with varying drug content were applied daily for periods of four 
days in randomised order five weeks after treatment by injection of testosterone enanthate. One 
treatment involved application of patches to the inner thigh, which necessitated an additional tape 
overlay. Following this study, patches were re-designed for the long-term study to be larger and to 
improve adhesiveness. Analysis of patch residual content indicated 30% absorption trans-scrotally 
and patients achieved normal testosterone levels over the one year treatment period. When applied 
to the thigh, no increases in serum testosterone were observed.  
 Subjective increases in sexual function were reported in a four-week study conducted with 5 
subjects using 40 cm2 and 60 cm2 patches (21). McClure et al. (34) evaluated both 40 cm2 and 60 cm2 
patches in a 12-week study on four subjects and reported restoration of normal sexual function with 
positive effects on mood and energy. The incidence of irritation with the scrotal patch was reported 
to be lower compared with the non-scrotal patches which were subsequently developed. However 
some patients did not have an adequate scrotal area to accommodate the patch; problems with 
adhesion of patches were also reported (35).  
 
Non-scrotal patches  
Reservoir type patches for application to non-scrotal skin were subsequently developed and 
evaluated in vitro and in vivo (36, 37). The reservoir consisted of testosterone, penetration 
enhancers and glycerine in a gelled vehicle. Patches were adhered to skin with a peripheral adhesive 
and a microporous membrane (not rate-limiting) separated the reservoir from the adhesive. The 
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active area of drug delivery of the patch was 7.5 cm2 and the testosterone loading of patches was 
12.5 mg. In vitro permeation studies suggested ~3.4 mg of testosterone would be delivered over 24 
h in vivo. For clinical studies two patches were applied nightly to various sites on the torso. In vivo 
studies were conducted both for a single patch application and for a four-week period of application.  
Physiological levels of DHT as well as testosterone were achieved, thus avoiding the first-pass 
metabolic effects of the scrotal patches. Non-scrotal patches were evaluated for a single application 
(two patches applied to the mid-back at night) and following a four-week period of application of 
two patches nightly to various parts of the upper body (37). For the single application patches were 
removed after 24 h and measurements were conducted over 48 h. An increase in baseline 
testosterone levels of 5.8 ± 0.9 n mol/L to an average peak value of 44.1 ± 4.8 nmol/L at 5.7 ± 0.6 h 
was observed; values subsequently decreased to 17 nmol/L for the remaining 12 h.  After removal of 
the patches the elimination half-life was 116 ± 17 min. For the four week study the average peak 
testosterone concentration was 33.5 ± 4.3 nmol/L, which was achieved after ~6 h application of the 
patches. A time-averaged testosterone level of 21.8 ± 4.3 nmol/L was also attained after this period 
of application. Steady state profiles of both testosterone and DHT mimicked normal daily variation. 
Residual content analysis of the patches indicated that drug input ranged from 3–7 mg/day. Patches 
were well tolerated with the exception of one subject who developed an allergy to one of the patch 
excipients. Subjective improvements were reported for sexual function and well-being for patients 
who were treated with trans-scrotal patches for 7 months (36).  
Arver et al. reported the pharmacokinetics of testosterone delivery from these patches as 
part of a multicentre, open-label study in 34 patients over a 12-month period (38). Testosterone 
levels were measured 12 h after patch application in the morning. Mean testosterone levels were 
522.6-642.1 ng/dL, and were within the normal range. The average testosterone level, based on 
assessment from months 3 to 12, was 599.8 ± 199.6 mg/dL. Normal circadian testosterone levels 
were observed with a morning peak of 740.9 ± 278.2 ng/dL and a night-time trough of 213.3 ± 80.0 
ng/dL. The DHT to testosterone ratio was within the normal range for healthy men. Sexual function 
was reported to improve significantly which was subjectively assessed using structured 
questionnaires and daily logs. 10 Patients reported skin irritation and subsequently three patients 
withdrew from the study because of this side effect. The most common adverse events were 
pruritus and mild or moderate erythema (15 subjects) and application site itch (15 subjects).  Blister 
reactions were also reported where patches were applied to bony prominences (6 patients).  
As part of the 12-month study reported by Arver et al. (38) the same authors also examined 
the influence of site of application of the patch on testosterone pharmacokinetics and metabolism 
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(39). In a sequential crossover design study two patches were applied for 24 h to the back, abdomen, 
upper arm, chest, shin or thigh. Sequential applications were separated by a minimum of 2 days (24 
h after the previous patches were applied).  Time averaged steady state testosterone concentrations 
(C’ss) for bioavailable testosterone (non-SHBG bound testosterone) for the sites were ranked as 
follows: back > thigh > upper arm > abdomen > chest > shin. To optimise testosterone delivery the 
authors suggested that the preferred sites for applying the patches should be the back, thigh, upper 
arm and abdomen. In addition, it was noted that no significant dermal metabolism of testosterone 
was evident at any of the sites tested.  
Yu et al. (40) conducted an open-label, randomized, crossover study to evaluate dose 
proportionality of non-scrotal patches (D-TRANS, Alza Corp). 19 Hypogonadal men were recruited 
and either one or two patches were applied daily for 7 days to the upper buttocks. Patches were 60 
cm2 in dimension with an estimated drug delivery of 5 mg per day.  As a positive control scrotal 
patches with the same dimensions and with a nominal delivery of 6 mg/day were also used. Plasma 
testosterone levels were similar for all treatments and mirrored normal testosterone levels. Average 
serum concentrations for placebo, scrotal patch, application of one patch and application of two 
patches were respectively 157 ±172, 403 ± 255, 570 ± 225 and 941 ± 382 ng/dL. Analysis of the log-
transformed normalised increased area under the curve (AUC) data indicated that serum levels of 
testosterone were proportional to patch surface area. All three treatments produced an early 
increase in plasma testosterone with maximal concentrations observed 2 to 4 h after patch 
application. Testosterone levels remained relatively stable over 24 h and on removal of patches, 
testosterone levels declined rapidly to near baseline. There were no statistically significant increases 
in the ratio of testosterone to DHT for the non-scrotal patches.  
 
5. Transdermal gel formulations  
Androgel™ 
There are several currently marketed transdermal testosterone gel formulations (Table 2). 
Androgel™ was the first preparation to become available (in June 2000) and within one year of 
launch supplanted patches as the preferred transdermal testosterone preparation of choice in the 
United States (41). This is a hydro-alcoholic gel formulation containing isopropyl myristate which the 
patient applies evenly to the shoulders/upper arms and/or abdomen area. The original Androgel™ 
preparation contained 1% w/w testosterone and more recently a formulation containing 1.62% w/w 
of drug has become available (Table 2). For the recommended starting dose of 50 mg testosterone 
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for Androgel™ 1%, and assuming an applied dose of 2 mg/cm2 the approximate area of application is 
~2,500 cm2.  Androgel™ 1.62 has a starting dose of 40.5 mg testosterone with an estimated area of 
application of ~1,250 cm2.  
A crossover study conducted by Wang et al. (42) in 9 subjects over 14 days indicated that 
steady state testosterone levels were achieved between 48 to 72 h after first application of the gel. 
Patients applied either one metered dose (25 mg) at the same site (left arm/shoulder) four times or 
at four separate sites (left and right arms/shoulders and left/right abdomen). Within 4 days of 
stopping the treatment testosterone serum levels returned to baseline. Mean AUC values were not 
significantly different (p>0.05) for gel applied at multiple sites versus gel applied repeatedly at one 
site. Based on mean serum testosterone concentration after gel application the authors also 
estimated the bioavailability of testosterone from the formulation was 9 to 14%.   
The efficacy of the gel compared with Androderm™ patches was evaluated by Swerdloff et 
al. (43) after 1, 30, 90 and 180 days application. Both the pharmacokinetics and tolerability of 50 and 
100 mg testosterone daily were evaluated in a randomised, multi-centre parallel study involving 227 
subjects.  Serum testosterone levels reached normal values within 1 day of treatment with either gel 
or patch. Average steady state levels of testosterone remained stable for the duration of treatment 
with the gel. Dose proportionality in serum testosterone levels was demonstrated for the different 
doses of gel. Although ratios of DHT to testosterone were raised following application of the gel, 
values remained within the normal range. Discontinuation rates indicated that the gel was 
significantly (p=0.0002) better tolerated by patients than the patch. Treatment with the gel also 
improved sexual mood and function, increased muscle mass and strength and decreased fat mass 
(44). Longer term studies confirmed these beneficial effects with no clinically significant changes in 
biochemistry or blood counts (45,46).  
Testim™ 
Testim™ was the second testosterone gel to become available (in February 2003) and it 
contains the penetration enhancer pentadecalactone in addition to a number of other components 
(Table 2). The gel is applied to the shoulders and upper arms; the area of application is ~2,500 cm2 
for a 50 mg testosterone starting dose. Marbury and co-workers (47) conducted a randomised 
crossover to compare the pharmacokinetics of Androgel™ versus Testim™. Formulations (50 mg 
testosterone) were applied to subjects with a 7-day interval between applications of the different 
preparations. Estimates of the maximum plasma concentration (Cmax) for total testosterone, free 
testosterone and DHT and AUC0-24 values were higher for Testim™ compared with Androgel™: the 
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authors concluded that the preparations were not bioequivalent. A randomised multi-centre study 
conducted by McNicholas et al. (48) over 90 days compared Testim™ with a patch formulation. Two 
doses of the gel (50 and 100 mg testosterone) were investigated and compared with a patch 
(Andropatch™, 2 x 12.2 mg testosterone). The gel formulation resulted in more favourable 
pharmacokinetic profiles than the patch which were also dose dependent. Testim™ also produced a 
significant decrease in body fat and improved sexual function compared with the patch. Patients 
tolerated the gel formulation better than the patch with higher rates of skin reactions and study 
withdrawal resulting from patch treatment. This is probably related to the non-occlusive nature of 
the gels used. Improved delivery of testosterone from Testim™ compared with Androderm™ was 
also reported by Steidle et al (49). This randomised, multicentre study involved 406 subjects and 
compared Testim™ (50 or 100 mg of testosterone) with a patch (Androderm™, 2 x 12.2 mg 
testosterone) formulation and placebo gel. Average testosterone plasma concentrations at day 90 
were 7.3, 11.9, 13.8 and 17.1 nmol/l for placebo, patch, 50 mg of gel and 100 mg of gel, respectively.  
Significant improvements in body mass and fat as well as sexual function were observed for the 100 
mg gel treatment compared with the patch and placebo. The results of two long term multicentre 
studies were later reported by Dean et al. (50) with the data supporting the results of the 90 day 
studies.  
Fortesta™ 
A third gel, Fortesta™, was approved by the FDA in 2010. This 2% testosterone formulation 
contains oleic acid (a known penetration enhancer) and is applied by the patient to the front and 
inner thighs rather than the upper body. For a 40 mg testosterone starting dose the estimated area 
of application is ~1,000 cm2. A multicentre open label clinical study conducted by Dobs et al. (51) 
over 90 days evaluated the efficacy, pharmacokinetics and safety of a 2% gel formulation in 129 
patients. Patients were supplied with a metered dosage pump with each actuation delivering 10 mg 
of testerosterone per 0.5 ml of gel. The starting dosage was 40 mg of testosterone with dose 
adjustment occurring depending on total serum testosterone levels at defined study intervals. At the 
end of the study period more than 75% of patients achieved normal testosterone levels; skin 
reactions were reported in 16% of patients. More recently Morgentaler et al (52) reported the 
results of a 14 day study conducted in 34 patients. Patients applied the gel (40 mg testosterone) once 
daily to the inner thighs. Normal testosterone levels were achieved within 3 h with steady state 
serum testosterone levels being achieved at a median time of 1.1 days. The median drying time of 
the gel was also reported as 2.4 min. Treatment related side effects were reported for 3 patients and 
included skin dryness, application site rash and diarrhoea.  
12 
 
Vogelxo™ 
The most recent transdermal testosterone gel formulation to be launched (July, 2014) is 
Vogelxo™. This formulation contains a number of penetration enhancers including diisopropyl 
adipate, methyl laurate and oleyl alcohol. Patients apply the gel to the shoulders and arms with a 
starting dose of 50 mg of testosterone. FDA approval was based on a multidose (50 or 100 mg of 
testosterone), multicentre clinical trial conducted over 90 days; 74% of patients (192 subjects) 
achieved normal testosterone levels by the end of the study. Skin irritation is listed as a potential 
side effect of the product (53). 
Secondary exposure to testosterone from gel formulations 
From 2000 to 2009 the FDA received a number of reports of inadvertent transfer of 
testosterone gels to children from patients. One or more of the following adverse events was 
reported in these children: advanced bone age, enlargement of sex organs, premature development 
of pubic hair, erections, increased self-stimulation, libido, and aggressive behaviour. In order to 
prevent inadvertent exposure of women and children to testosterone gels patients are instructed to 
wash their hands after using the product, to ensure treated sites are covered with clothing once the 
gel has dried and to wash treated skin sites if skin-to-skin contact is anticipated (54). The potential 
unwanted exposure to others, prompted the issuance of a draft guidance in 2013 in relation to 
applications for approval of generic testosterone gels. These will only be received if the proposed gel 
formulation is qualitatively and quantitatively the same as the reference listed drug (55). 
 
6. Transdermal testosterone liquid formulation - Axiron™ 
 A transdermal testosterone formulation for application to the axillae, using an applicator 
rather than the hands, was approved in 2010. This product is a solution and it contains the 
penetration enhancer octyl salicylate as well as ethanol, isopropanol and povidone. In pilot studies 
application of the formulation to the axillary region resulted in higher serum testosterone 
concentrations compared with application to the inner forearm. An open label study conducted over 
120 days evaluated the pharmacokinetics and efficacy of the formulation (56). Patients used a 
pump-actuated device to apply the formulation (30 mg testosterone per 1.5 ml) with a starting dose 
of 60 mg of drug. Where necessary, dosage was adjusted to maintain testosterone levels within the 
normal range. More than 80% of patients achieved normal testosterone levels with significant 
improvements also reported in sexual function and general physical and mental health.  The adverse 
events reported included application site irritation, application site erythema, headache, increased 
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haematocrit, nasopharyngitis, diarrhoea and vomiting. An extension to this primary study to 180 
days was used to analyse further the type and/or severity of skin reactions observed (57). 
Application site irritation and erythema were the most common problems but were classified as mild 
in severity. Although application to the axillae should reduce the risk of inadvertent transfer of the 
product to others patients are instructed to follow similar precautions as for gel preparations to 
prevent secondary testosterone exposure.  
 
7. Safety concerns related to transdermal testosterone therapy 
An increased incidence of prostate events and haematocrit values >50% was flagged in a 
meta-analysis of intramuscular, oral and transdermal delivery; there was no evidence that 
testosterone therapy increases prostate cancer (58). A number of recent publications reporting 
respectively on a clinical trial, a retrospective study, an observational study and a meta-analysis have 
raised concerns about cardiovascular risks associated with testosterone replacement therapy (59-
62). However Corona et al. (63) reported no evidence of cardiovascular risk based on a meta-analysis 
of 75 studies. An alert that this issue was being investigated by the FDA was issued by the agency in 
January 2014. The influence of route of testosterone administration on adverse events was recently 
evaluated by Borst et al. (64) who conducted two meta-analyses of 67 clinical studies. Oral 
administration of testosterone was associated with a significant increase in cardiovascular risk; no 
significant increase was noted for transdermal or injectable testosterone. In addition, the authors 
suggested that further research was necessary to determine whether administration by the latter 
two routes was protective or detrimental. Transdermal testosterone was also noted to result in 
significantly raised DHT levels compared with intramuscular administration.  
 
8. Alternative uses of transdermal testosterone 
The application of androgens for male contraception was initially evaluated in the 1970’s 
(65,66). Male hormonal contraception requires the delivery of either exogenous testosterone alone 
or in combination with a progestogen in order to suppress LH and FSH secretion from the pituitary. A 
combination of testosterone gel and injections of depomedroxyprogesterone acetate was studied in 
38 men over 24 weeks (67). Levels of spermatogenesis achieved were comparable with implantable 
and injectable combinations of testosterone and progestogen. The ability of testosterone and 
nestorone gels to suppress LH and FSH levels was evaluated by Mahabadi et al. (68). Although 
nestorone alone demonstrated gonadotrophin suppression, significant effects were observed for 
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combination of the gels. In a later study in 56 males the combination regimen was shown to 
suppress spermatogenesis to levels consistent with infertility in 88.5% of subjects (69).  
 
9. Summary and outlook  
The delivery of drugs transdermally was pioneered by Alza in the late 70’s and early 80’s but 
some 30 years later it is evident that very few of the many actives on the market have appropriate 
properties to be delivered by this route. Transdermal testosterone replacement therapy has come of 
age with a variety of technologies currently available compared with other actives delivered via the 
skin. The transdermal route is appropriate for testosterone because of its physicochemical and 
pharmacological properties. Despite the success of the delivery of testosterone, there is still a need 
to produce formulations, which minimise irritancy, are cosmetically acceptable and have good 
patient compliance. Although gel and roll-on formulations address some of these requirements, they 
have introduced the added risk of unwanted exposure to others; similar safety issues will be 
pertinent for spray formulations. Safety concerns in relation to cardiovascular risks of testosterone 
replacement therapy also remain controversial and the outcome of an ongoing regulatory review 
should provide some clarification. The potential of transdermal testosterone for contraception is 
actively being investigated but longer term studies are needed. 
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Table 1: Physicochemical and pharmacokinetic properties of testosterone  
Molecular weighta 288.4 
Melting pointa 152-157°C 
Log P a 3.3 
Solubilityb  0.04 mg/ml at 37oC 
Half-life c 10-100 min 
Protein bindingd 97-98% 
Clearancee 1272 ± 168 L/day 
a
Moffat et al. (7)  
b
Cichon and Janicki (8) 
c
Sandberg and Slaunwhite (9); Hellman and Rosenfeld (10) 
d
AHFS Drug Information ( 11) 
e
Wang et al. (12) 
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Table 2: Examples of commercial transdermal testosterone preparations  
Brand name Formulation  Composition  
Androderm™  
(Watson Laboratories)  
Patch 
 
2 mg/day, 32 cm2 
4 mg/day, 39 cm2 
Testosterone, alcohol, glycerin, glycerol 
monooleate, methyl laurate, sodium 
hydroxide, purified water, Carbomer  
Copolymer Type B 
 
Polyethylene microporous membrane 
Peripheral adhesive  
Testoderm TTS™  
(Brand name drug no longer 
available in the US) 
Patch 
 
5 mg/ day, 60 cm2 
Testosterone, alcohol, 
hydroxypropylcellulose 
 
Ethylene-vinyl acetate co-polymer 
membrane with polyisobutylene coating  
Testoderm™ 
(Brand name drug no longer 
available in the US) 
Scrotal Patch 
 
4 mg/day, 40 cm2 
5 mg/day, 60 cm2 
Testosterone, ethylene-vinyl acetate co-
polymer 
Androgel™ 
(AbbVie) 
Gel  
 
1 % w/w 
Testosterone, ethanol, isopropyl 
myristate, purified water, sodium 
hydroxide 
Androgel 1.62™ 
(AbbVie) 
Gel 
 
1.62 % w/w  
Testosterone, Carbopol 980, ethyl 
alcohol, isopropyl myristate, purified 
water, sodium hydroxide 
Testim™ 
(Auxilium Pharmaceuticals) 
Gel 
 
1 % w/w  
Testosterone, acrylates, Carbopol, 
ethanol, glycerin, pentadecalactone, 
polyethylene glycol,  propylene glycol, 
purified water,  tromethamine 
Fortesta™ 
(Endo Pharmaceuticals) 
Gel 
 
2 % w/w 
Testosterone, butylated hydroxytoluene, 
Carbomer 1382, ethanol, oleic acid, 
propylene glycol, purified water, 2-
propanol, triethanolamine  
Vogelxo™ 
(Upsher-Smith Laboratories) 
Gel 
 
1% w/w  
Testosterone, Carbomer copolymer Type 
B, Carbomer homopolymer Type C, 
diisopropyl adipate, ethyl alcohol, 
glycerin, methyl laurate, oleyl alcohol, 
polyethylene glycol, propylene glycol, 
purified water, tromethamine 
Axiron™ 
(Licensed in the US to Eli Lilly)  
Solution  
 
30 mg / 1.5 mL 
Testosterone, ethanol, isopropyl alcohol, 
octyl salicylate, povidone. 
 
 
